Immune Tolerance Study With Aldurazyme® (Laronidase)

NCT ID: NCT00741338

Last Updated: 2014-07-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-09-30
• Study Completion Date: 2012-09-30

Brief Summary

The purpose of this study is to see if treatment with an antigen-specific immunosuppressive can decrease or stop an antibody response to laronidase (Aldurazyme®) during enzyme replacement therapy with laronidase in severe Mucopolysaccharidosis I (MPS I) participants.

Conditions

Mucopolysaccharidosis I

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1

Tolerance Induction Period (TIP): Cyclosporine A (CsA) starting at 5 milligram per kilogram (mg/kg) orally three times daily until the target trough concentration of at least 350 nanogram per milliliter (ng/mL) (preferably 400 ng/mL) achieved along with azathioprine (Aza) 2.5 mg/kg/day orally. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly intravenous (IV) infusion (starting from Day 1) up to Week 12. CsA and Aza were gradually discontinued. Immune Challenge Period (ICP): following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 39.

Group Type: EXPERIMENTAL

Laronidase

Intervention Type: BIOLOGICAL

0.058 mg/kg - 0.58 mg/kg IV infusion weekly.

Cyclosporine A (CsA)

Intervention Type: DRUG

Orally three times daily.

Azathioprine (Aza)

Intervention Type: DRUG

Orally either every day for Cohort 1 or every other day for Cohort 2.

Cohort 2

TIP: CsA starting at 6.7 mg/kg orally three times daily until the target trough concentration of at least 350 ng/mL (preferably 400 ng/mL) achieved along with Aza 5 mg/kg orally every other day. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly IV infusion (starting from Day 1) up to Week 18. CsA and Aza were gradually discontinued. ICP: following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 45.

Group Type: EXPERIMENTAL

Laronidase

Intervention Type: BIOLOGICAL

0.058 mg/kg - 0.58 mg/kg IV infusion weekly.

Cyclosporine A (CsA)

Intervention Type: DRUG

Orally three times daily.

Azathioprine (Aza)

Intervention Type: DRUG

Orally either every day for Cohort 1 or every other day for Cohort 2.

Interventions

Laronidase

0.058 mg/kg - 0.58 mg/kg IV infusion weekly.

Intervention Type: BIOLOGICAL

Cyclosporine A (CsA)

Orally three times daily.

Intervention Type: DRUG

Azathioprine (Aza)

Orally either every day for Cohort 1 or every other day for Cohort 2.

Intervention Type: DRUG

Other Intervention Names

Aldurazyme®; Neoral®; Imuran®

Eligibility Criteria

Inclusion Criteria

• Written informed consent is required from the parent(s) or legal guardian(s) prior to any protocol-related procedures being performed. (A separate informed consent will be requested from the parent(s) for their genotyping, which is independent of the inclusion)
• Participant's parent(s) or legal guardian(s) allow their child's participation and are willing and able to comply with trial procedures
• The participant must be up to and including 5 years of age at the time of enrollment
• Clinical diagnosis of the severe (Hurler) phenotype of MPS I
• Confirmed presence of 2 nonsense mutations in the alfa-L-iduronidase (IDUA) gene (that is, compound heterozygosity or homozygosity). For the purpose of enrollment, genotyping may be performed by a local laboratory. If no genotyping is performed by a local laboratory, a sample is collected for analysis by a central laboratory before enrollment
• Documented IDUA deficiency with fibroblast, plasma, serum, leukocyte or dried blood spot IDUA enzyme activity assay

Exclusion Criteria

• The participant has a clinically significant organ disease including: cardiovascular, hepatic, pulmonary, neurologic, or renal disease, other serious intercurrent illness or extenuating circumstances that, in the opinion of the investigator, precludes participation in the trial or potentially decrease survival
• The participant has previously received treatment with laronidase
• The participant has known severe hypersensitivity to any excipients of the delivery solution for laronidase or to any of the other investigational drugs used in the study
• The participant has undergone a haematopoietic stem cell transplant (HSCT), regardless of outcome, or is currently under consideration for such a transplant. If a family later decides to obtain HSCT, the participant will be discontinued from the trial
• The participant has received an investigational product within the 30 days prior to enrollment
• The participant has prior treatment in any experimental protocol (for example, fibroblast injections) that might potentially induce antibodies to laronidase or might affect the interpretation of the participant's antibody response to laronidase
• The participant has received vaccination(s) within 1 month prior to enrollment, or is unwilling to postpone vaccinations during the Tolerance Induction Period in the trial
• The participant is homozygous for thiopurine methyltransferase (TPMT) deficiency, as determined by the genotype (the presence of 2 known null alleles for TPMT) or phenotype (near to complete absence of TPMT enzyme activity)
• The participant has a prior history of tuberculosis or a positive test for latent tuberculosis infection

• Maximum Eligible Age: 5 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BioMarin/Genzyme LLC

INDUSTRY

Sponsor Role: collaborator

Genzyme, a Sanofi Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor

Role: STUDY_DIRECTOR

Genzyme Europe B.V.

Locations

HCPA

Porto Alegre, , Brazil

Moscow Research Institute for Pediatrics and Children Surgery

Moscow, , Russia

Countries

Brazil; Russia

References

Giugliani R, Vieira TA, Carvalho CG, Munoz-Rojas MV, Semyachkina AN, Voinova VY, Richards S, Cox GF, Xue Y. Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. Mol Genet Metab Rep. 2017 Jan 13;10:61-66. doi: 10.1016/j.ymgmr.2017.01.004. eCollection 2017 Mar.

Reference Type: DERIVED

PMID: 28119821 (View on PubMed)

Other Identifiers

2007-001163-30

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ALID02307

Identifier Type: -

Identifier Source: org_study_id